nach oben

European Archives of Oto-Rhino-Laryngology

Erschienen in:

11.01.2016 | Review Article

Perspectives in chemosensitivity and chemoresistance assays and their implementation in head and neck cancer

verfasst von: Lara Bussmann, Chia-Jung Busch, Balazs B. Lörincz, Thorsten Rieckmann, Andreas Block, Rainald Knecht

Erschienen in: European Archives of Oto-Rhino-Laryngology | Ausgabe 12/2016

Einloggen, um Zugang zu erhalten

Abstract

Therapeutic options for patients with head and neck squamous cell carcinoma include surgery, radiation and chemotherapy. The latter plays a major role in the treatment selection of recurrent, metastatic or therapy resistant tumours, these being some of the major challenges in head and neck oncology. For these patients, chemosensitivity and chemoresistance assays would be paramount to identify their individual therapy options. In this review, seven common assays will be described and discussed in the context of several studies. Further, a new assay will also be presented, currently being validated in a European Union funded project. Comparisons will be drawn to evaluate the sensitivity and specificity of these assays in identifying individual treatment options, and their potential implementation in head and neck malignancies will be discussed. There is an unmet demand for the development of ex vivo diagnostic tools that may predict response in head and neck cancer on the way towards an individualized treatment for these patients.

Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108CrossRefPubMed

Houchens DP, Ovejera AA, Hrsg (1978) Proceedings of the symposium on the use of athymic (nude) mice in Cancer research, 1977. Fischer, New York

Petty RD, Sutherland LA, Hunter EM et al (1995) Comparison of MTT and ATP-based assays for the measurement of viable cell number. J Biolumin Chemilumin 10:29–34CrossRefPubMed

Maenpaa JU, Heinonen E, Hinkka SM et al (1995) The subrenal capsule assay in selecting chemotherapy for ovarian cancer: a prospective randomized trial. Gynecol Oncol 57:294–298CrossRefPubMed

Price KAR, Cohen EE (2012) Current treatment options for metastatic head and neck cancer. Curr Treat Options Oncol 13:35–46CrossRefPubMed

Burstein HJ, Mangu PB, Somerfield MR et al (2011) American society of clinical oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. J Clin Oncol 29:3328–3330CrossRefPubMed

Whitehouse PA, Knight LA, Di Nicolantonio F et al (2003) Heterogeneity of chemosensitivity of colorectal adenocarcinoma determined by a modified ex vivo ATP-tumour chemosensitivity assay (ATP-TCA). Anticancer Drugs 14:369–375CrossRefPubMed

Hamburger AW, Salmon SE (1977) Primary bioassay of human tumour stem cells. Science 197:461–463CrossRefPubMed

Ang KK, Sturgis EM (2012) Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma. Semin Radiat Oncol 22:128–142CrossRefPubMed

10.

Hamburger A, Salmon SE (1977) Primary bioassay of human myeloma stem cells. J Clin Investig 60:846–854CrossRefPubMedPubMedCentral

11.

Mirghani H, Amen F, Moreau F et al (2014) Oropharyngeal cancers: relationship between epidermal growth factor receptor alterations and human papillomavirus status. Eur J Cancer (Oxford, England: 1990) 50:1100–1111

12.

Samson DJ, Seidenfeld J, Ziegler K et al (2004) Chemotherapy sensitivity and resistance assays: a systematic review. J Clin Oncol 22:3618–3630CrossRefPubMed

13.

Wu B, Zhu J, Zhang Y et al (2008) Predictive value of MTT assay as an in vitro chemosensitivity testing for gastric cancer: one institution’s experience. World J Gastroenterol 14:3064–3068CrossRefPubMedPubMedCentral

14.

Cree IA, Pazzagli M, Mini E et al (1995) Methotrexate chemosensitivity by ATP luminescence in human leukemia cell lines and in breast cancer primary cultures: comparison of the TCA-100 assay with a clonogenic assay. Anticancer Drugs 6:398–404CrossRefPubMed

15.

Mehta RS, Bornstein R, Yu IR et al (2001) Breast cancer survival and in vitro tumour response in the extreme drug resistance assay. Breast Cancer Res Treat 66:225–237CrossRefPubMed

16.

Von Hoff DD, Kronmal R, Salmon SE et al (1991) A southwest oncology group study on the use of a human tumour cloning assay for predicting response in patients with ovarian cancer. Cancer 67:20–27CrossRef

17.

Suonio E, Lipponen P, Maenpaa J et al (1997) Mitotic index in the subrenal capsule assay as an indicator of the chemosensitivity of ovarian cancer. Cancer Chemother Pharmacol 41:15–21CrossRefPubMed

18.

Shaw GL, Gazdar AF, Phelps R et al (1996) Correlation of in vitro drug sensitivity testing results with response to chemotherapy and survival: comparison of non-small cell lung cancer and small cell lung cancer. J Cell Biochem Suppl 24:173–185CrossRefPubMed

19.

Cortazar P, Gazdar AF, Woods E et al (1997) Survival of patients with limited-stage small cell lung cancer treated with individualized chemotherapy selected by in vitro drug sensitivity testing. Clin Cancer Res 3:741–747PubMed

20.

Maurer HR, Ali-Osman F (1981) Tumour stem cell cloning in agar-containing capillaries. Naturwissenschaften 68:381–383CrossRefPubMed

21.

Ali-Osman F, Beltz PA (1988) Optimization and characterization of the capillary human tumour clonogenic cell assay. Cancer Res 48:715–724PubMed

22.

Von Hoff DD, Sandbach JF, Clark GM et al (1990) Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician. J Natl Cancer Inst 82:110–116CrossRef

23.

Weisenthal LM, Marsden JA, Dill PL et al (1983) A novel dye exclusion method for testing in vitro chemosensitivity of human tumours. Cancer Res 43:749–757PubMed

24.

Weisenthal LM, Dill PL, Kurnick NB et al (1983) Comparison of dye exclusion assays with a clonogenic assay in the determination of drug-induced cytotoxicity. Cancer Res 43:258–264PubMed

25.

Andreotti PE, Cree IA, Kurbacher CM et al (1995) Chemosensitivity testing of human tumours using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 55:5276–5282PubMed

26.

Chen F, Cushion MT (1994) Use of an ATP bioluminescent assay to evaluate viability of Pneumocystis carinii from rats. J Clin Microbiol 32:2791–2800PubMedPubMedCentral

27.

Ling Z, Qi C, Lu X et al (2012) Heterogeneity of chemosensitivity in esophageal cancer using ATP-tumour chemosensitivity assay. Acta Pharmacol Sin 33:401–406CrossRefPubMedPubMedCentral

28.

Sharma S, Neale MH, Di Nicolantonio F et al (2003) Outcome of ATP-based tumour chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma. BMC Cancer 3:19CrossRefPubMedPubMedCentral

29.

Meyer T, Nelstrop AE, Mahmoudi M et al (2001) Weekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer. Ann Oncol 12:1705–1709CrossRefPubMed

30.

Kern DH, Drogemuller CR, Kennedy MC et al (1985) Development of a miniaturized, improved nucleic acid precursor incorporation assay for chemosensitivity testing of human solid tumours. Cancer Res 45:5436–5441PubMed

31.

Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63CrossRefPubMed

32.

Furukawa T, Kubota T, Watanabe M et al (1992) High in vitro-in vivo correlation of drug response using sponge-gel-supported three-dimensional histoculture and the MTT end point. Int J Cancer J Int du Cancer 51:489–498CrossRef

33.

Furukawa T, Kubota T, Hoffman RM (1995) Clinical applications of the histoculture drug response assay. Clin Cancer Res 1:305–311PubMed

34.

Bogden AE, Kelton DE, Cobb WR, Esber HJ (1978) A rapid screening method for testing chemotherapeutic agents against human tumour xenografts. In: Houchens DP, Ovejera AA (eds) Proceedings of the symposium on the use of athymic (nude) mice in Cancer research, 1977. Fischer, New York

35.

Singh B, Li R, Xu L et al (2002) Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head Neck 24:437–442CrossRefPubMed

36.

Hasegawa Y, Goto M, Hanai N et al (2007) Evaluation of optimal drug concentration in histoculture drug response assay in association with clinical efficacy for head and neck cancer. Oral Oncol 43:749–756CrossRefPubMed

37.

Schuler PJ, Trellakis S, Greve J et al (2010) In vitro chemosensitivity of head and neck cancer cell lines. Eur J Med Res 15:337–344CrossRefPubMedPubMedCentral

38.

Hoffmann TK, Sonkoly E, Hauser U et al (2008) Alterations in the p53 pathway and their association with radio- and chemosensitivity in head and neck squamous cell carcinoma. Oral Oncol 44:1100–1109CrossRefPubMed

39.

Martens-de Kemp SR, Dalm SU, Wijnolts FMJ et al (2013) DNA-bound platinum is the major determinant of cisplatin sensitivity in head and neck squamous carcinoma cells. PLoS ONE 8:e61555CrossRefPubMedPubMedCentral

40.

Erjala K, Raitanen M, Kulmala J et al (2007) Concurrent use of vinorelbine and gefitinib induces supra-additive effect in head and neck squamous cell carcinoma cell lines. J Cancer Res Clin Oncol 133:169–176CrossRefPubMed

41.

Vermorken JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. New Engl J Med 359:1116–1127CrossRefPubMed

42.

Seiwert TY, Haddad RI, Gupta S et al (2015) Antitumour activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): preliminary results from KEYNOTE-012 expansion cohort. ASCO Meet Abstr 33:LBA6008

43.

Dollner R, Granzow C, Helmke BM et al (2004) The impact of stromal cell contamination on chemosensitivity testing of head and neck carcinoma. Anticancer Res 24:325–331PubMed

44.

Dollner R, Granzow C, Neudert M et al (2006) Ex vivo chemosensitivity of head and neck carcinoma to cytostatic drug combinations. Anticancer Res 26:1651–1655PubMed

45.

Bogden AE, Von Hoff DD (1984) Comparison of the human tumour cloning and subrenal capsule assays. Cancer Res 44:1087–1090PubMed

46.

Rhedin AS, Tidefelt U, Jonsson K et al (1993) Comparison of a bioluminescence assay with differential staining cytotoxicity for cytostatic drug testing in vitro in human leukemic cells. Leuk Res 17:271–276CrossRefPubMed

47.

Ole Thastrup. ICSC (integrated chemical synthesis and screening in patient cells). Im Internet: http://cordis.europa.eu/result/rcn/58199_en.html. Accessed 14 Sep 2014

48.

Broder GR, Birtwell SW, Hagel G, Thastrup O, Morgan H, Roach PL (2011) Multiplex bioassays using a suspension array platform; towards the high throughput screening of drugs targeting cancer stem cells. In: Verpoorte S, Hrsg (eds) 14th International Conference on Miniaturized Systems for Chemistry and Life Sciences 2010. (MicroTAS 2010): Groningen, The Netherlands, 3–7 October 2010. San Diego, Calif., Red Hook, NY: Chemical and Biological Microsystems Society; Printed from e-media with permission by Curran Associates, Inc., vol c2010, pp 185–1387

49.

Horizon 2020 newsroom editor. Better combination therapies for colorectal cancer patients. http://ec.europa.eu/programmes/horizon2020/en/news/better-combination-therapies-colorectal-cancer-patients. Accessed 14 Sep 2015

Titel: Perspectives in chemosensitivity and chemoresistance assays and their implementation in head and neck cancer
verfasst von: Lara Bussmann
Chia-Jung Busch
Balazs B. Lörincz
Thorsten Rieckmann
Andreas Block
Rainald Knecht
Publikationsdatum: 11.01.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: European Archives of Oto-Rhino-Laryngology / Ausgabe 12/2016
Print ISSN: 0937-4477
Elektronische ISSN: 1434-4726
DOI: https://doi.org/10.1007/s00405-015-3893-1

Neu im Fachgebiet HNO

16.04.2024 | HNO-Chirurgie | Nachrichten

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Perspectives in chemosensitivity and chemoresistance assays and their implementation in head and neck cancer

Abstract

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

RRP: Adjuvante HPV-Impfung in jedem Alter empfehlenswert

Update HNO

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2016

Prevalence of human papillomavirus in oral squamous cell carcinomas in northern Spain

Pharmacological agents used for treatment and prevention in noise-induced hearing loss

Efficacy of chlorophyll c2 for seasonal allergic rhinitis: single-center double-blind randomized control trial

Association between vascular supply, stage and tumour size of juvenile nasopharyngeal angiofibroma

Predisposing factors for adverse skin reactions with percutaneous bone anchored hearing devices implanted with skin reduction techniques

The preservation of swollen middle ear mucosa could be important to the post-tympanoplasty audiologic outcome

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

RRP: Adjuvante HPV-Impfung in jedem Alter empfehlenswert

Update HNO